NSAID Labeling Revisions Revised By FDA; Compliance Date Extended
This article was originally published in The Tan Sheet
Executive Summary
FDA has deleted the part of its recommended heart risk warning for NSAIDs that discourages use for "longer than 10 days or more than the recommended dose.
You may also be interested in...
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
Health Canada Report: No OTC NSAID Label Changes Needed
Canadian manufacturers of nonprescription ibuprofen products will not have to make any label changes regarding cardiovascular risks that may be associated with the non-steroidal anti-inflammatory drugs class, Health Canada states in documents released June 14
Wyeth’s Advil PM Approved By FDA; Sleep Aid To Challenge Tylenol PM?
Wyeth is entering the combination sleep aid/pain reliever category with its new Advil PM, recently approved by FDA for over-the-counter sale